Cost-Effectiveness of Empagliflozin in Patients With Diabetic Kidney Disease in the United States: Findings Based on the EMPA-REG OUTCOME Trial-Reference-Cited by-同舟云学术

Cost-Effectiveness of Empagliflozin in Patients With Diabetic Kidney Disease in the United States: Findings Based on the EMPA-REG OUTCOME Trial

Published:2021-11 Issue: Volume: Page:
ISSN:0272-6386
Container-title:American Journal of Kidney Diseases
language:en
Short-container-title:American Journal of Kidney Diseases

Author:

Reifsnider Odette S.,Kansal Anuraag R.,Wanner Christoph,Pfarr Egon,Koitka-Weber Audrey,Brand Sarah B.,Stargardter Matthew,Wang Cheng,Kuti Effie,Ustyugova Anastasia

Funder

Boehringer Ingelheim International GmbH

Publisher

Elsevier BV

Subject

Nephrology

Reference41 articles.

1. Kidney disease and increased mortality risk in type 2 diabetes;Afkarian;J Am Soc Nephrol,2013

2. Clinical manifestations of kidney disease among US adults with diabetes, 1988-2014;Afkarian;JAMA,2016

3. Epidemiology of diabetic kidney disease;Reutens;Med Clin North Am,2013

4. Cost of treating diabetic kidney disease;Dasgupta;Indian J Nephrol,2014

5. The landscape of diabetic kidney disease in the United States;Duru;Curr Diab Rep,2018

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. SGLT2 Inhibitor Use in Chronic Kidney Disease: Supporting Cardiovascular, Kidney, and Metabolic Health;Kidney Medicine;2024-08

2. Cost Offset of Dapagliflozin in the US Medicare Population with Cardio-Kidney Metabolic Syndrome;Advances in Therapy;2024-07-03

3. Cost-effectiveness of add-on empagliflozin versus standard of care in management of CKD in Malaysia, Thailand and Vietnam – findings from a modelling study assessing an EMPA-KIDNEY eligible population, using CKD progression model;Journal of Medical Economics;2024-07

4. Long-Term Outcomes of Heart Failure With Preserved or Mid-Range Ejection Fraction in the United States;JACC: Advances;2024-07

5. Cost-effectiveness of empagliflozin as add-on to standard of care for chronic kidney disease management in the United Kingdom;Journal of Medical Economics;2024-06-05